[5-(1-ethyl-piperidin-4-ylsulfanyl)-pyridin-2-yl]-[4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine | 1231930-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: [5-(1-ethyl-piperidin-4-ylsulfanyl)-pyridin-2-yl]-[4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine
• 英文别名: N-[5-(1-ethylpiperidin-4-yl)sulfanylpyridin-2-yl]-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
• CAS: 1231930-11-2
• 化学式: C₂₇H₃₂FN₇S
• 分子量: 505.662
• InChiKey: RHWLOGCPVFAMEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：COATES David A.

  公开号：US20100160340A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

  本发明提供了化合物的结构式(I)：或其药用可接受的盐，可用于治疗细胞增殖性疾病。
• Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US20170224819A1

  公开（公告）日：2017-08-10

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.
• US7855211B2
  申请人：——

  公开号：US7855211B2

  公开（公告）日：2010-12-21